Diplomat Pharmacy Inc (NYSE:DPLO) has been given a consensus rating of “Hold” by the fourteen brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $26.67.

A number of brokerages have recently commented on DPLO. ValuEngine cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. Morgan Stanley boosted their price objective on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 3rd. Finally, Leerink Swann reissued an “outperform” rating and issued a $33.00 price objective on shares of Diplomat Pharmacy in a research note on Friday, June 22nd.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 209,367 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of the business’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. Insiders own 24.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy in the 1st quarter worth about $104,000. United Services Automobile Association purchased a new stake in shares of Diplomat Pharmacy in the 2nd quarter worth about $210,000. D.A. Davidson & CO. purchased a new stake in shares of Diplomat Pharmacy in the 2nd quarter worth about $215,000. UBS Group AG boosted its position in shares of Diplomat Pharmacy by 186.4% in the 1st quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after buying an additional 5,526 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Diplomat Pharmacy in the 2nd quarter worth about $225,000. Institutional investors own 80.89% of the company’s stock.

Shares of Diplomat Pharmacy stock traded up $0.25 during trading on Friday, reaching $18.31. The company’s stock had a trading volume of 91,314 shares, compared to its average volume of 974,667. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 21.58 and a beta of 1.13. Diplomat Pharmacy has a fifty-two week low of $14.50 and a fifty-two week high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63.

Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Monday, August 6th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.06). The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The business’s revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.25 earnings per share. Analysts anticipate that Diplomat Pharmacy will post 0.83 earnings per share for the current year.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.